BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

425 related articles for article (PubMed ID: 19296417)

  • 1. Impact of guidelines on outcome: the evidence.
    Martínez R; Reyes S; Lorenzo MJ; Menéndez R
    Semin Respir Crit Care Med; 2009 Apr; 30(2):172-8. PubMed ID: 19296417
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibiotic prescription for community-acquired pneumonia in the intensive care unit: impact of adherence to Infectious Diseases Society of America guidelines on survival.
    Bodí M; Rodríguez A; Solé-Violán J; Gilavert MC; Garnacho J; Blanquer J; Jimenez J; de la Torre MV; Sirvent JM; Almirall J; Doblas A; Badía JR; García F; Mendia A; Jordá R; Bobillo F; Vallés J; Broch MJ; Carrasco N; Herranz MA; Rello J;
    Clin Infect Dis; 2005 Dec; 41(12):1709-16. PubMed ID: 16288392
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Empiric treatment in hospitalized community-acquired pneumonia. Impact on mortality, length of stay and re-admission.
    Reyes Calzada S; Martínez Tomas R; Cremades Romero MJ; Martínez Moragón E; Soler Cataluña JJ; Menéndez Villanueva R
    Respir Med; 2007 Sep; 101(9):1909-15. PubMed ID: 17628462
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Medical outcomes and antimicrobial compliance according to the Chilean Society of Respiratory Diseases guidelines for hospitalized patients with community acquired pneumonia].
    Díaz A; Kuzmanic G; Platzer L; Sanfuentes F; Espinoza MA; Saldías F
    Rev Med Chil; 2003 Aug; 131(8):847-56. PubMed ID: 14558238
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improvement of process-of-care and outcomes after implementing a guideline for the management of community-acquired pneumonia: a controlled before-and-after design study.
    Capelastegui A; España PP; Quintana JM; Gorordo I; Ortega M; Idoiaga I; Bilbao A
    Clin Infect Dis; 2004 Oct; 39(7):955-63. PubMed ID: 15472846
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early switch to oral antibiotics and early discharge guidelines in the management of community-acquired pneumonia.
    Lee RW; Lindstrom ST
    Respirology; 2007 Jan; 12(1):111-6. PubMed ID: 17207035
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early and late treatment failure in community-acquired pneumonia.
    Garcia-Vidal C; Carratalà J
    Semin Respir Crit Care Med; 2009 Apr; 30(2):154-60. PubMed ID: 19296415
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of new therapies for severe community-acquired pneumonia.
    Restrepo MI; Anzueto A
    Curr Opin Infect Dis; 2006 Dec; 19(6):557-64. PubMed ID: 17075331
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adherence to infectious diseases society of America guidelines for empiric therapy for patients with community-acquired pneumonia in a commercially insured cohort.
    Wu JH; Howard DH; McGowan JE; Turpin RS; Henry Hu X
    Clin Ther; 2006 Sep; 28(9):1451-61. PubMed ID: 17062317
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The halo effect of adherence to guidelines extends to patients with severe community-acquired pneumonia requiring admission to an intensive care unit.
    Marrie TJ
    Clin Infect Dis; 2005 Dec; 41(12):1717-9. PubMed ID: 16288393
    [No Abstract]   [Full Text] [Related]  

  • 11. Evidence for moxifloxacin in community-acquired pneumonia: the impact of pharmaco-economic considerations on guidelines.
    Simoens S
    Curr Med Res Opin; 2009 Oct; 25(10):2447-57. PubMed ID: 19678752
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Community acquired bacterial pneumonia.
    Anevlavis S; Bouros D
    Expert Opin Pharmacother; 2010 Feb; 11(3):361-74. PubMed ID: 20085502
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparison of levofloxacin and moxifloxacin use in hospitalized community-acquired pneumonia (CAP) patients in the US: focus on length of stay.
    Schein J; Janagap-Benson C; Grant R; Sikirica V; Doshi D; Olson W
    Curr Med Res Opin; 2008 Mar; 24(3):895-906. PubMed ID: 18419876
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New guidelines for the management of adult community-acquired pneumonia.
    Armitage K; Woodhead M
    Curr Opin Infect Dis; 2007 Apr; 20(2):170-6. PubMed ID: 17496576
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of guideline-concordant empiric antibiotic therapy in community-acquired pneumonia.
    Frei CR; Restrepo MI; Mortensen EM; Burgess DS
    Am J Med; 2006 Oct; 119(10):865-71. PubMed ID: 17000218
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In-hospital observation after antibiotic switch in pneumonia: a national evaluation.
    Nathan RV; Rhew DC; Murray C; Bratzler DW; Houck PM; Weingarten SR
    Am J Med; 2006 Jun; 119(6):512.e1-7. PubMed ID: 16750965
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of guidelines on the outcomes of community-acquired and ventilator-associated pneumonia.
    Ferrer M; Menendez R; Amaro R; Torres A
    Clin Chest Med; 2011 Sep; 32(3):491-505. PubMed ID: 21867818
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Do guidelines for community-acquired pneumonia improve the cost-effectiveness of hospital care?
    Nathwani D; Rubinstein E; Barlow G; Davey P
    Clin Infect Dis; 2001 Mar; 32(5):728-41. PubMed ID: 11229840
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibiotic therapy for community-acquired pneumonia with septic shock: follow the guidelines.
    Blot S; Depuydt P
    Crit Care Med; 2007 Jun; 35(6):1617-8. PubMed ID: 17522537
    [No Abstract]   [Full Text] [Related]  

  • 20. Initial antibiotic selection and patient outcomes: observations from the National Pneumonia Project.
    Bratzler DW; Ma A; Nsa W
    Clin Infect Dis; 2008 Dec; 47 Suppl 3():S193-201. PubMed ID: 18986289
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.